At this point, about 6 million Americans have taken free Paxlovid doses
SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients
SGLT-2is associated with lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists, metformin
FDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants
Immunocompromised patients can still receive convalescent plasma
Studies Compare Various Treatments for COVID-19
Sotrovimab effective compared with molnupiravir; second study shows no effect for angiotensin receptor blockers in terms of illness severity
ACR: Long-Term Safety Demonstrated for Anifrolumab in Lupus
Exposure-adjusted incidence rates of serious adverse events 8.5 versus 11.2 per 100 patient-years for anifrolumab versus placebo
Telehealth Tied to Higher Buprenorphine Retention
Substantial number of Veterans Health Administration patients received buprenorphine from phone-only telehealth
Disparities ID’d in Dispensing of Oral Antivirals for COVID-19
Substantial disparities seen in dispensing rates in high social-vulnerability zip codes versus medium-, low-vulnerability zip codes
Pirfenidone Promising for RA-Linked Interstitial Lung Disease
Phase 2 trial terminated early, underpowered to meet primary end point, but limited results suggest pirfenidone may slow progression of RA-ILD
Bebtelovimab Appears Reliable for COVID-19 During Omicron Epoch
Patients receiving bebtelovimab have more comorbidities, but do not have increased rates of progression to severe disease
Twelfth Version of Living Guideline Issued for Drugs for COVID-19
New update strongly recommends against use of sotrovimab and casirivimab-imdevimab for patients with COVID-19